The Benefits of Restorative Programming for Skilled Nursing Facilities 
Biotricity Delivers Bioheart, A Groundbreaking Consumer Heart Monitor
Continuous monitoring device with advanced features and analytics to deliver personalized insights directly to the smartphone REDWOOD CITY, Calif.--(BUSINESS WIRE)--Biotricity,...
Vibrent Health Leverages AI-Based Technology to Build a Tool Improving COVID Response
New AI tool helps proactively screen, test and identify people at risk for COVID FAIRFAX, Va.--(BUSINESS WIRE)--Vibrent Health, a...
Sensei Launches Golf And Tennis Optimal Wellbeing Programs
LOS ANGELES, Nov. 10, 2021 /PRNewswire/ -- Building on the success of the Optimal Wellbeing Program (OWP) that launched in...
Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results
Ovid is implementing its business development program which intends to secure a series of opportunities that complement and enhance its...
Bluejay Diagnostics, Inc. Announces Pricing of Upsized $21.6 Million Initial Public Offering
ACTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company...
Pharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights
RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks, proceeding; topline data reaffirmed for 2022CHAPTER-1, Phase...
Outlook Therapeutics to Present at the Virtual Investor Roundtable Event
Live moderated video webcast discussion among members of management and Thought Leaders Firas M. Rahhal, MD and Robert L. Avery,...
Arcutis to Present at Upcoming Investor Conference
WESTLAKE VILLAGE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing...
EDAP TMS SA to Announce Third Quarter 2021 Financial Results on Wednesday, November 17, 2021
Company to host conference call and webcast on Thursday, November 18, at 8:30 am ET LYON, France, November 10, 2021...
SalioGen Therapeutics Appoints Esteemed Industry Veterans to Executive Advisory Board
John Maraganore, Ph.D., Mark McClellan, M.D., Ph.D. and Andrew Lo, Ph.D. appointed as Executive Advisors to support SalioGen’s efforts to...
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel...
Rain Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Progress
New Phase 2 clinical trial planned for milademetan in Merkel cell carcinoma (MCC), the MANTRA-3 trial, to start in mid-2022...
ChemoCentryx to Participate in Two Upcoming Investor Conferences
SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D.,...
Pyxis Oncology to Present at the Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), today announced that management will present at and...
Ayala Pharmaceuticals to Present at Jefferies London Healthcare Conference
REHOVOT, Israel and WILMINGTON, Del., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company...
Levitee Labs Signs Letter of Intent to Acquire a Chain of Specialty Addiction Pharmacies Located in British Columbia
Signed LOI to acquire 100% interest in chain of specialty addiction pharmacies in Vancouver, BCAcquisition price of $4.0 million based...
Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
In-person and virtual Presentation: November 10-14th, 2021ROCHESTER, N.Y., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage...
Vaccitech to Present at the Jefferies London Healthcare Conference
OXFORD, United Kingdom, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the...
Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy with Curative Potential for RAG1 Severe Combined Immunodeficiency
Agreement expands Mustang’s pipeline of lentiviral gene therapies for SCID Preclinical development of additional targets to continue at Leiden University...
BioSyent Schedules Q3 and YTD 2021 Earnings Release for November 18, 2021
MISSISSAUGA, Ontario, Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its...